Targeted Treatments of Non-Small Cell Lung Cancer: Skin Toxicity

Molecularly targeted therapy (MTT) is advancing rapidly in oncology, particularly for non-small cell lung cancer (NSCLC), with Epidermal Growth Factor Receptor Inhibitors (EGFRIs) offering longer progression-free survival. However, EGFRIs often lead to skin toxicity, which is more frequent and severe compared to traditional chemotherapy and radiation. Dermatotropic side effects can occur in 47–100% of patients, with xerosis cutis, pruritus, paronychia, hair growth abnormalities, and mucositis being common. Skin toxicity is more prevalent with monoclonal antibodies than tyrosine kinase inhibitors. The article discusses the classification of skin toxicity, its impact on quality of life, and management strategies, including skin care and medication, supported by clinical examples from the author's practice.